Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-008563
Filing Date
2022-05-12
Accepted
2022-05-12 16:24:04
Documents
73
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rzlt-20220331x10q.htm   iXBRL 10-Q 1384649
2 EX-31.1 rzlt-20220331xex31d1.htm EX-31.1 15301
3 EX-32.1 rzlt-20220331xex32d1.htm EX-32.1 7348
  Complete submission text file 0001558370-22-008563.txt   6928888

Data Files

Seq Description Document Type Size
4 EX-101.SCH rzlt-20220331.xsd EX-101.SCH 65372
5 EX-101.CAL rzlt-20220331_cal.xml EX-101.CAL 42560
6 EX-101.DEF rzlt-20220331_def.xml EX-101.DEF 253723
7 EX-101.LAB rzlt-20220331_lab.xml EX-101.LAB 404988
8 EX-101.PRE rzlt-20220331_pre.xml EX-101.PRE 412028
67 EXTRACTED XBRL INSTANCE DOCUMENT rzlt-20220331x10q_htm.xml XML 1217599
Mailing Address 201 REDWOOD SHORES PARKWAY, SUITE 315 REDWOOD CITY CA 94065
Business Address 201 REDWOOD SHORES PARKWAY, SUITE 315 REDWOOD CITY CA 94065 650-847-1919
Rezolute, Inc. (Filer) CIK: 0001509261 (see all company filings)

EIN.: 273440894 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-39683 | Film No.: 22918191
SIC: 2834 Pharmaceutical Preparations